The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience

被引：36

作者：

Ayhan, A

Gultekin, M ^{[1
]}

Taskiran, C

Aksan, G

Celik, NY

Dursun, P

Salman, MC

Yuce, K

Kucukali, T

机构：

[1] Hacettepe Univ, Fac Med, Dept Obstet & Gynecol, Div Gynecol Oncol, TR-06100 Ankara, Turkey

[2] Hacettepe Univ, Fac Med, Dept Pathol, TR-06100 Ankara, Turkey

来源：

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY | 2006年 / 194卷 / 01期

关键词：

epithelial ovarian carcinoma; recurrent ovarian carcinoma; secondary cytoreduction; optimal debulking;

D O I：

10.1016/j.ajog.2005.06.048

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Objective: This study was undertaken to evaluate the role of secondary cytoreduction in patients with recurrent epithelial ovarian cancer. Study design: Secondarily, cytoreduced patients were retrospectively analyzed with respect to the clinicopathologic variables. Results: A total of 64 patients were evaluated in this report. Multivariable analysis revealed 3 factors to be significant: optimal cytoreduction during primary (P = .003, odds ratio [OR]: 0.30; 95% CI: 0.14-0.66), secondary cytoreduction (P = .04, OR: 0.47; 95% CI: 0.22-0.99), and the endometrioid histologic type (P = .005, OR: 0.09; 95% CI: 0.02-0.48). Intrinsic factors of the tumors (grade, stage, age), size, and number of recurrent tumors were nonsignificant. Conclusion: Secondary cytoreduction surgery should be offered in selected recurrent epithelial ovarian cancer patients. Further prospective randomized series are needed to determine specific recommendations. (c) 2006 Mosby, Inc. All rights reserved.

引用

页码：49 / 56

页数：8

共 30 条

[1]

BEREK JS, 1983, OBSTET GYNECOL, V61, P189

[2]

Chen LM, 2000, SEMIN SURG ONCOL, V19, P62, DOI 10.1002/1098-2388(200007/08)19:1<62::AID-SSU10>3.0.CO

[3]

2-O

[4]

EISENKOP SM, 1995, CANCER, V76, P1606, DOI 10.1002/1097-0142(19951101)76:9<1606::AID-CNCR2820760917>3.0.CO

[5]

2-H

[6]

Eisenkop SM, 2000, CANCER, V88, P144, DOI 10.1002/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.0.CO

[7]

2-X

[8] Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer [J].

Gadducci, A ;

Iacconi, P ;

Cosio, S ;

Fanucchi, A ;

Cristofani, R ;

Genazzani, AR .

GYNECOLOGIC ONCOLOGY, 2000, 79 (03) :344-349

[9] Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum [J].

Gronlund, B ;

Lundvall, L ;

Christensen, IJ ;

Knudsen, JB ;

Hogdall, C .

EJSO, 2005, 31 (01) :67-73

[10] The role of secondary cytoreductive surgery for recurrent ovarian cancer [J].

Güngör, M ;

Ortaç, F ;

Arvas, M ;

Kösebay, D ;

Sönmezer, M ;

Köse, K .

GYNECOLOGIC ONCOLOGY, 2005, 97 (01) :74-79

← 1 2 3 →